JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

Published on 10/15/2026 at 21:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 71.26 million. Rhythm Pharmaceuticals stock costs EUR 79.00 on October 15, 2026, up 2.35 percent on Nasdaq.

JPMorgan target and earnings

JPMorgan lowered its target from USD 146.00 to USD 145.00 on October 15, 2026.
Second-quarter revenue reached USD 71.26 million, while the adjusted loss was USD 0.73 per share versus USD 0.81 expected.
Rhythm Pharmaceuticals stock costs EUR 79.00 at Lang & Schwarz on October 15, 2026 at 9:07 p.m. CEST, up 2.35 percent on Nasdaq.
Rhythm Pharmaceuticals is scheduled to report its next results on November 3, 2026.

RYTM, US76243J1051, Illustration mit AI erstellt.

JPMorgan Chase cut its price target for Rhythm Pharmaceuticals from USD 146.00 to USD 145.00 in a research note dated October 15, 2026, while keeping an Overweight rating, as MarketBeat reported. Against the Nasdaq quote of USD 88.75 on October 15, 2026, the new target stood 63.38 percent higher. At Lang & Schwarz, the euro quote was EUR 79.00 on October 15, 2026 at 9:07 p.m. CEST, while Nasdaq trading was up 2.35 percent from USD 86.71.

Revenue reached USD 71.26 million

Rhythm's second-quarter revenue reached USD 71.26 million, according to Investing.com. The figure was 5.52 percent above the USD 67.53 million consensus estimate. The company also posted a loss of USD 0.73 per share, narrower than the expected USD 0.81 loss, a 9.88 percent difference on the same basis.

Price sits below the yearly high

The Nasdaq quote of USD 88.75 on October 15, 2026 at 3:11 p.m. ET was 27.37 percent below the 52-week high of USD 122.20 and 19.12 percent above the USD 74.50 low. Trading volume was 245,140 shares against an average of 672,464 shares. The euro quote at Lang & Schwarz stood at EUR 79.00 on October 15, 2026 at 9:07 p.m. CEST.

Valuation and November results date

Rhythm Pharmaceuticals had a market capitalization of USD 6.1 billion and a negative P/E ratio of 28.54 as of October 15, 2026. The company does not currently pay a dividend. Gekko lists November 3, 2026 as the next earnings date and puts the consensus target at USD 138.59 from 14 firms.

Comparison with peers

RYTM (NASDAQ, USD): plus 2.35 percent, P/E minus 28.54, market capitalization USD 6.1 billion

Altimmune (NASDAQ, USD): plus 0.87 percent, P/E minus 2.98, market capitalization USD 453.2 million

Structure Therapeutics (NASDAQ, USD): plus 1.39 percent, P/E minus 7.32, market capitalization USD 1.3 billion

Trading position and next date

The analyst target remains materially above the Nasdaq quote, while the latest quarterly revenue figure provides a concrete operating measure for the November reporting date. The Nasdaq quote was up 2.35 percent on October 15, 2026, whereas the Lang & Schwarz indication was EUR 79.00 at 9:07 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Rhythm Pharmaceuticals stock.